RADNOR, Pa., March 18, 2016 -- Kessler Topaz Meltzer & Check, LLP files shareholder class action lawsuit against Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or the “Company”) on behalf of purchasers of the Company’s securities between March 3, 2015 and January 25, 2016, inclusive (the “Class Period”).
Insys shareholders who wish to submit their information or request additional information about the lawsuit are encouraged to contact Kessler Topaz Meltzer & Check attorneys D. Seamus Kaskela, Esq. or Adrienne O. Bell, Esq. at (888) 299-7706 or online at https://www.ktmc.com/new-cases/insys-therapeutics-inc.
The class action complaint alleges that Insys and certain of its executive officers made a series of false and misleading statements and failed to disclose material adverse facts about the Company’s business and operations to investors during the Class Period. Specifically, the defendants are alleged to have failed to disclose that: (i) the Company was engaged in the illegal and improper off-labeling marketing of Subsys; (ii) certain Insys employees—including Defendant Michael L. Babich, the President and Chief Executive Officer of Insys during much of the Class Period—were complicit in an illegal kickback scheme operated for the purpose of increasing prescriptions of Subsys; and (iii) as a result, the Company’s financial statements were materially false and misleading at all relevant times.
Insys shareholders who purchased their securities during the Class Period (March 3, 2015 – January 25, 2016) may, no later than April 4, 2016, petition the Court to be appointed as a lead plaintiff representative of the class.
A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. Members of the purported class may petition the Court through Kessler Topaz Meltzer & Check or other counsel, or may choose to do nothing and remain an absent class member. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class in the action. Your ability to share in any recovery is not affected by the decision of whether or not to petition the Court to be appointed as a lead plaintiff.
Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check, or for additional information about participating in this action, please visit www.ktmc.com.
CONTACT: Kessler Topaz Meltzer & Check, LLP Darren J. Check, Esq. D. Seamus Kaskela, Esq. Adrienne O. Bell, Esq. 280 King of Prussia Road Radnor, PA 19087 (888) 299-7706


Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 



